About this Journal Submit a Manuscript Table of Contents 
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 518094, 20 pages
http://dx.doi.org/10.1155/2013/518094
Review Article

Mediators of Inflammation-Induced Bone Damage in Arthritis and Their Control by Herbal Products

Siddaraju M. Nanjundaiah,1 Brian Astry,1 and Kamal D. Moudgil1,2

1Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2Division of Rheumatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Received 9 August 2012; Revised 6 December 2012; Accepted 10 December 2012

Academic Editor: Cheorl-Ho Kim

Copyright © 2013 Siddaraju M. Nanjundaiah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Takayanagi, “Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems,” Nature Reviews Immunology, vol. 7, no. 4, pp. 292–304, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Rajaiah, Y. Yang, S. R. Satpute, M. Durai, and K. D. Moudgil, “Immunopathogenesis and treatment of autoimmune arthritis in animal models,” in Recent Research Developments in Rheumatology, A. La Cava, Ed., pp. 1–30, Research Signpost Publishers, Trivandrum, India, 2008.
  3. R. Rajaiah and K. D. Moudgil, “Animal models,” in Rheumatoid Arthritis, M. C. Hochberg, A. J. Silman, J. S. Smolen, M. E. Weinblatt, and M. H. Weisman, Eds., pp. 218–224, Mosby; Elsevier, 2009.
  4. S. H. Venkatesha, B. Astry, S. M. Nanjundaiah, H. Yu, and K. D. Moudgil, “Suppression of autoimmune arthritis by celastrus-derived celastrol through modulation of pro-inflammatory chemokines,” Bioorganic & Medicinal Chemistry, vol. 20, no. 17, pp. 5229–5234, 2012. View at Publisher · View at Google Scholar
  5. A. Morinobu, W. Biao, S. Tanaka et al., “(-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice,” Arthritis and Rheumatism, vol. 58, no. 7, pp. 2012–2018, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Roy, S. Sannigrahi, R. P. Vaddepalli, B. Ghosh, and P. Pusp, “A novel combination of methotrexate and epigallocatechin attenuates the overexpression of pro-inflammatory cartilage cytokines and modulates antioxidant status in adjuvant arthritic rats,” Inflammation, vol. 35, no. 4, pp. 1435–1447, 2012. View at Publisher · View at Google Scholar
  7. J. H. Lee, H. Jin, H. E. Shim, H. N. Kim, H. Ha, and Z. H. Lee, “Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-κB signal,” Molecular Pharmacology, vol. 77, no. 1, pp. 17–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. D. O. Moon, M. O. Kim, Y. H. Choi, Y. M. Park, and G. Y. Kim, “Curcumin attenuates inflammatory response in IL-1β-induced human synovial fibroblasts and collagen-induced arthritis in mouse model,” International Immunopharmacology, vol. 10, no. 5, pp. 605–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Kim, K. Kim, H. M. Jin et al., “Silibinin inhibits osteoclast differentiation mediated by TNF family members,” Molecules and Cells, vol. 28, no. 3, pp. 201–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. H. Venkatesha, H. Yu, R. Rajaiah, L. Tong, and K. D. Moudgil, “Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses,” The Journal of Biological Chemistry, vol. 286, no. 17, pp. 15138–15146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Nanjundaiah, S. H. Venkatesha, H. Yu, L. Tong, J. P. Stains, and K. D. Moudgil, “Celastrus and its bioactive Celastrol protect against bone damage in autoimmune arthritis by modulating the osteo-immune crosstalk,” The Journal of Biological Chemistry, vol. 287, no. 26, pp. 22216–22226, 2012. View at Publisher · View at Google Scholar
  12. J. B. Jiang, J. D. Qiu, L. H. Yang, J. P. He, G. W. Smith, and H. Q. Li, “Therapeutic effects of astragalus polysaccharides on inflammation and synovial apoptosis in rats with adjuvant-induced arthritis,” International Journal of Rheumatic Diseases, vol. 13, no. 4, pp. 396–405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Sethi, S. A. Kwang, M. K. Pandey, and B. B. Aggarwal, “Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation,” Blood, vol. 109, no. 7, pp. 2727–2735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Lee, T. H. Koo, H. Yoon et al., “Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoid,” Biochemical Pharmacology, vol. 72, no. 10, pp. 1311–1321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Li, D. He, X. Zhang et al., et al., “Protective effect of celastrol in rat cerebral ischemia model: down-regulating p-JNK, p-c-Jun and NF-kappaB,” Brain Research, vol. 1464, pp. 8–13, 2012.
  16. X. Pang, Z. Yi, J. Zhang et al., “Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway,” Cancer Research, vol. 70, no. 5, pp. 1951–1959, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. C. Gupta, J. H. Kim, S. Prasad, and B. B. Aggarwal, “Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals,” Cancer and Metastasis Reviews, vol. 29, no. 3, pp. 405–434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Xuzhu, M. Komai-Koma, B. P. Leung, et al., “Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function,” Annals of the Rheumatic Diseases, vol. 71, no. 1, pp. 129–135, 2012.
  19. M. Lei, S. Q. Liu, and Y. L. Liu, “Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1β,” Acta Pharmacologica Sinica, vol. 29, no. 11, pp. 1350–1356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. C. Hsu, C. P. Cheng, and D. M. Chang, “Plectranthus amboinicus attenuates inflammatory bone erosion in mice with collagen-induced arthritis by downregulation of RANKL-induced NFATc1 expression,” Journal of Rheumatology, vol. 38, no. 9, pp. 1844–1857, 2011.
  21. M. L. Sharma, S. Bani, and G. B. Singh, “Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis,” International Journal of Immunopharmacology, vol. 11, no. 6, pp. 647–652, 1989. View at Scopus
  22. A. Goel, F. J. Ahmad, R. M. Singh, and G. N. Singh, “3-Acetyl-11-keto-β-boswellic acid loaded-polymeric nanomicelles for topical anti-inflammatory and anti-arthritic activity,” Journal of Pharmacy and Pharmacology, vol. 62, no. 2, pp. 273–278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. S. Park, J. H. Lee, J. A. Harwalkar, J. Bondar, H. Safayhi, and M. Golubic, “Acetyl-11-keto-β-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2,” Advances in Experimental Medicine and Biology, vol. 507, pp. 387–393, 2002. View at Scopus
  24. A. B. Kunnumakkara, A. S. Nair, B. Sung, M. K. Pandey, and B. B. Aggarwal, “Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1,” Molecular Cancer Research, vol. 7, no. 1, pp. 118–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Takada, H. Ichikawa, V. Badmaev, and B. B. Aggarwal, “Acetyl-11-keto-β-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression,” Journal of Immunology, vol. 176, no. 5, pp. 3127–3140, 2006. View at Scopus
  26. X. Pang, Z. Yi, X. Zhang et al., “Acetyl-11-keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis,” Cancer Research, vol. 69, no. 14, pp. 5893–5900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. D. W. Goldman, L. A. Gifford, R. N. Young, T. Marotti, M. K. L. Cheung, and E. J. Goetzl, “Affinity labeling of the membrane protein-binding component of human polymorphonuclear leukocyte receptors for leukotriene B4,” Journal of Immunology, vol. 146, no. 8, pp. 2671–2677, 1991. View at Scopus
  28. X. Z. Zhang, Y. Zhang, and W. G. Shen, “Effect of genistein on MAPK signal pathway in the collagen-induced arthritis fibroblast-like synoviocytes,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 31, no. 10, pp. 1405–1408, 2011.
  29. V. Saratha and S. P. Subramanian, “Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats,” Inflammopharmacology, vol. 20, no. 1, pp. 27–37, 2012.
  30. A. S. A. Levy, O. Simon, J. Shelly, and M. Gardener, “6-Shogaol reduced chronic inflammatory response in the knees of rats treated with complete Freund's adjuvant,” BMC Pharmacology, vol. 6, article 12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Ling, H. Yang, S. H. Tan, W. K. Chui, and E. H. Chew, “6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-κB activation,” British Journal of Pharmacology, vol. 161, no. 8, pp. 1763–1777, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Kawaguchi, H. Maruyama, R. Hasunuma, and Y. Kumazawa, “Suppression of inflammatory responses after onset of collagen-induced arthritis in mice by oral administration of the Citrus flavanone naringin,” Immunopharmacology and Immunotoxicology, vol. 33, no. 4, pp. 723–729, 2011.
  33. K. Kawaguchi, H. Maruyama, T. Kometani, and Y. Kumazawa, “Suppression of collagen-induced arthritis by oral administration of the Citrus flavonoid hesperidin,” Planta Medica, vol. 72, no. 5, pp. 477–479, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. K. M. Kalff, M. El Mouedden, J. van Egmond et al., “Pre-treatment with capsaicin in a rat osteoarthritis model reduces the symptoms of pain and bone damage induced by monosodium iodoacetate,” European Journal of Pharmacology, vol. 641, no. 2-3, pp. 108–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. P. Hwang, H. J. Yun, J. H. Choi et al., “Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling,” Molecular Nutrition and Food Research, vol. 55, no. 4, pp. 594–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Sassa, T. Kikuchi, H. Shinoda, S. Suzuki, H. Kudo, and S. Sakamoto, “Preventive effect of ferulic acid on bone loss in ovariectomized rats,” In Vivo, vol. 17, no. 3, pp. 277–280, 2003. View at Scopus
  37. D. Impellizzeri, E. Esposito, E. Mazzon, et al., “Oleuropein aglycone, an olive oil compound, ameliorates development of arthritis caused by injection of collagen type II in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 339, no. 3, pp. 859–869, 2011.
  38. M. Tsuji, H. Yamamoto, T. Sato et al., “Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice,” Journal of Bone and Mineral Metabolism, vol. 27, no. 6, pp. 673–681, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. S. Sung, E. G. Lee, H. S. Jeon, et al., “Quercetin inhibits IL-1beta-induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast,” Inflammation, vol. 35, no. 4, pp. 1585–1594, 2012.
  40. Y. S. Hsieh, S. C. Chu, S. F. Yang, P. N. Chen, Y. C. Liu, and K. H. Lu, “Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2,” Carcinogenesis, vol. 28, no. 5, pp. 977–987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Chen, Z. Yin, and X. Zheng, “Effect and mechanism of total flavonoids of orange peel on rat adjuvant arthritis,” Zhongguo Zhongyao Zazhi, vol. 35, no. 10, pp. 1298–1301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Miyake, K. Ide, K. Sasaki, Y. Matsukura, K. Shijima, and D. Fujiwara, “Oral administration of highly oligomeric procyanidins of Jatoba reduces the severity of collagen-induced arthritis,” Bioscience, Biotechnology and Biochemistry, vol. 72, no. 7, pp. 1781–1788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. T. M. Haqqi, D. D. Anthony, S. Gupta et al., “Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4524–4529, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. H. R. Kim, R. Rajaiah, Q.-L. Wu, et al., “Green tea protects rats against autoimmune arthritis by modulating disease-related immune events,” Journal of Nutrition, vol. 138, no. 11, pp. 2111–2116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. K. Park, J. S. Park, M. L. Cho et al., “Grape seed proanthocyanidin extract (GSPE) differentially regulates Foxp3+ regulatory and IL-17+ pathogenic T cell in autoimmune arthritis,” Immunology Letters, vol. 135, no. 1-2, pp. 50–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. V. Gay, V. R. Gilman, and T. Sugiyama, “Perspectives on osteoblast and osteoclast function,” Poultry Science, vol. 79, no. 7, pp. 1005–1008, 2000. View at Scopus
  47. A. J. Kahn and N. C. Partridge, “New concepts in bone remodeling: an expanding role for the osteoblast,” American Journal of Otolaryngology, vol. 8, no. 5, pp. 258–264, 1987. View at Scopus
  48. M. Zaidi, “Skeletal remodeling in health and disease,” Nature Medicine, vol. 13, no. 7, pp. 791–801, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. P. J. Marie, “Signaling pathways affecting skeletal health,” Current Osteoporosis Reports, vol. 10, no. 3, pp. 190–198, 2012.
  50. F. D. S. Rabelo, L. M. H. da Mota, R. A. C. Lima et al., “The Wnt signaling pathway and rheumatoid arthritis,” Autoimmunity Reviews, vol. 9, no. 4, pp. 207–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Suda, N. Takahashi, and T. J. Martin, “Modulation of osteoclast differentiation,” Endocrine Reviews, vol. 13, no. 1, pp. 66–80, 1992. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Y. Kong, H. Yoshida, I. Sarosi et al., “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,” Nature, vol. 397, no. 6717, pp. 315–323, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. F. P. Ross, “M-CSF, c-Fms, and signaling in osteoclasts and their precursors,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 110–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Khosla, “Minireview: the OPG/RANKL/RANK system,” Endocrinology, vol. 142, no. 12, pp. 5050–5055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Rifas, S. Arackal, and M. N. Weitzmann, “Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts,” Journal of Cellular Biochemistry, vol. 88, no. 4, pp. 650–659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Nakamura, M. F. Pilkington, P. T. Lakkakorpi et al., “Role of α(v)β3 integrin in osteoclast migration and formation of the sealing zone,” Journal of Cell Science, vol. 112, no. 22, pp. 3985–3993, 1999. View at Scopus
  57. H. Kajiya, F. Okamoto, K. Ohgi, A. Nakao, H. Fukushima, and K. Okabe, “Characteristics of ClC7 Cl- channels and their inhibition in mutant (G215R) associated with autosomal dominant osteopetrosis type II in native osteoclasts and hClcn7 gene-expressing cells,” Pflugers Archiv European Journal of Physiology, vol. 458, no. 6, pp. 1049–1059, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. B. R. Troen, “The role of Cathepsin K in normal bone resorption,” Drug News and Perspectives, vol. 17, no. 1, pp. 19–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Galli, G. Passeri, and G. M. MacAluso, “Critical reviews in oral biology & medicine: osteocytes and WNT: the mechanical control of bone formation,” Journal of Dental Research, vol. 89, no. 4, pp. 331–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. L. F. Bonewald and M. L. Johnson, “Osteocytes, mechanosensing and Wnt signaling,” Bone, vol. 42, no. 4, pp. 606–615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. D. H. Jones, Y. Y. Kong, and J. M. Penninger, “Role of RANKL and RANK in bone loss and arthritis,” Annals of the Rheumatic Diseases, vol. 61, supplement 2, pp. ii32–ii39, 2002. View at Scopus
  62. B. R. Wong, J. Rho, J. Arron et al., “TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells,” The Journal of Biological Chemistry, vol. 272, no. 40, pp. 25190–25194, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. W. C. Dougall, M. Glaccum, K. Charrier et al., “RANK is essential for osteoclast and lymph node development,” Genes and Development, vol. 13, no. 18, pp. 2412–2424, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. J. E. Fata, Y. Y. Kong, J. Li et al., “The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development,” Cell, vol. 103, no. 1, pp. 41–50, 2000. View at Scopus
  65. H. Hsu, D. L. Lacey, C. R. Dunstan et al., “Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3540–3545, 1999. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Nakagawa, M. Kinosaki, K. Yamaguchi et al., “RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis,” Biochemical and Biophysical Research Communications, vol. 253, no. 2, pp. 395–400, 1998. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Wada, T. Nakashima, N. Hiroshi, and J. M. Penninger, “RANKL-RANK signaling in osteoclastogenesis and bone disease,” Trends in Molecular Medicine, vol. 12, no. 1, pp. 17–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, vol. 89, no. 2, pp. 309–319, 1997. View at Scopus
  69. H. Yasuda, N. Shima, N. Nakagawa et al., “Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro,” Endocrinology, vol. 139, no. 3, pp. 1329–1337, 1998. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Min, S. Morony, I. Sarosi et al., “Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis,” Journal of Experimental Medicine, vol. 192, no. 4, pp. 463–474, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. J. G. Emery, P. McDonnell, M. B. Burke et al., “Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL,” The Journal of Biological Chemistry, vol. 273, no. 23, pp. 14363–14367, 1998. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Faccio, S. Takeshita, G. Colaianni et al., “M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559/697/721,” The Journal of Biological Chemistry, vol. 282, no. 26, pp. 18991–18999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. P. V. Hauschka and F. H. Wians Jr., “Osteocalcin-hydroxyapatite interaction in the extracellular organic matrix of bone,” Anatomical Record, vol. 224, no. 2, pp. 180–188, 1989. View at Scopus
  74. M. Magaro, L. Altomonte, L. Mirone, A. Zoli, and A. Tricerri, “Serum osteocalcin as an index of bone turnover in active rheumatoid arthritis and in active psoriatic arthritis,” Clinical Rheumatology, vol. 8, no. 4, pp. 494–498, 1989. View at Scopus
  75. H. Yoshitake, S. R. Rittling, D. T. Denhardt, and M. Noda, “Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 14, pp. 8156–8160, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Asou, S. R. Rittling, H. Yoshitake et al., “Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone,” Endocrinology, vol. 142, no. 3, pp. 1325–1332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Take, K. Nakata, J. Hashimoto et al., “Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6,” Arthritis and Rheumatism, vol. 60, no. 12, pp. 3591–3601, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Astry, E. Harberts, and K. D. Moudgil, “A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis,” Journal of Interferon & Cytokine Research, vol. 31, no. 12, pp. 927–940, 2011.
  79. D. J. Cua and C. M. Tato, “Innate IL-17-producing cells: the sentinels of the immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 479–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Kotake, N. Udagawa, N. Takahashi et al., “IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis,” Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345–1352, 1999. View at Scopus
  81. I. E. Adamopoulos, C. C. Chao, R. Geissler et al., “Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors,” Arthritis Research and Therapy, vol. 12, no. 1, article R29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Yago, Y. Nanke, N. Ichikawa et al., “IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: a novel mechanism of osteoclastogenesis by IL-17,” Journal of Cellular Biochemistry, vol. 108, no. 4, pp. 947–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Murugaiyan, A. Mittal, and H. L. Weiner, “Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis,” Journal of Immunology, vol. 181, no. 11, pp. 7480–7488, 2008. View at Scopus
  84. J. A. Gracie, R. J. Forsey, W. L. Chan et al., “A proinflammatory role for IL-18 in rheumatoid arthritis,” Journal of Clinical Investigation, vol. 104, no. 10, pp. 1393–1401, 1999. View at Scopus
  85. J. H. Ruth, C. C. Park, M. A. Amin et al., “Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis,” Arthritis Research & Therapy, vol. 12, no. 3, Article ID R118, 2010.
  86. M. V. Volin and A. E. Koch, “Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis,” Journal of Interferon & Cytokine Research, vol. 31, no. 10, pp. 745–751, 2011.
  87. S. M. Dai, K. Nishioka, and K. Yudoh, “Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1β and tumour necrosis factor α,” Annals of the Rheumatic Diseases, vol. 63, no. 11, pp. 1379–1386, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. C. Makiishi-Shimobayashi, T. Tsujimura, T. Iwasaki et al., “Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells,” Biochemical and Biophysical Research Communications, vol. 281, no. 2, pp. 361–366, 2001. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Udagawa, N. J. Horwood, J. Elliott et al., “Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation,” Journal of Experimental Medicine, vol. 185, no. 6, pp. 1005–1012, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Yamamura, M. Kawashima, M. Taniai, et al., “Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 44, no. 2, pp. 275–285, 2001.
  91. K. T. Steeve, P. Marc, T. Sandrine, H. Dominique, and F. Yannick, “IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology,” Cytokine and Growth Factor Reviews, vol. 15, no. 1, pp. 49–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Ma, K. Miyanishi, A. Suen et al., “Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-α,” Cytokine, vol. 26, no. 3, pp. 138–144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Kobayashi, N. Takahashi, E. Jimi et al., “Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction,” Journal of Experimental Medicine, vol. 191, no. 2, pp. 275–286, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Kim, Y. Kadono, M. Takami et al., “Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis,” Journal of Experimental Medicine, vol. 202, no. 5, pp. 589–595, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Mabilleau, F. Pascaretti-Grizon, M. F. Basle, and D. Chappard, “Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT,” Cytokine, vol. 57, no. 2, pp. 294–299, 2012.
  96. T. Mori, T. Miyamoto, H. Yoshida, et al., “IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis,” International Immunology, vol. 23, no. 11, pp. 701–712, 2011.
  97. K. Kanbe, A. Nakamura, Y. Inoue, and K. Hobo, “Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis,” Rheumatology International, vol. 32, no. 9, pp. 2669–2674, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Honda, “Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes,” Journal of Oral Science, vol. 53, no. 1, pp. 87–96, 2011.
  99. B. R. Troen, “The regulation of cathepsin K gene expression,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 165–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. F. Zhang, H. Tanaka, T. Kawato et al., “Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts,” Biochimie, vol. 93, no. 2, pp. 296–305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. G. Murphy and M. H. Lee, “What are the roles of metalloproteinases in cartilage and bone damage?” Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. iv44–iv47, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Yoshihara, H. Nakamura, K. Obata et al., “Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis,” Annals of the Rheumatic Diseases, vol. 59, no. 6, pp. 455–461, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. M. T. Engsig, Q. J. Chen, T. H. Vu et al., “Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones,” Journal of Cell Biology, vol. 151, no. 4, pp. 879–889, 2000. View at Publisher · View at Google Scholar · View at Scopus
  104. G. C. N. Franco, M. Kajiya, T. Nakanishi et al., “Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo,” Experimental Cell Research, vol. 317, no. 10, pp. 1454–1464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. D. V. Jovanovic, J. Martel-Pelletier, J. A. Di Battista et al., “Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 43, no. 5, pp. 1134–1144, 2000.
  106. A. E. Kossakowska, D. R. Edwards, C. Prusinkiewicz et al., “Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas,” Blood, vol. 94, no. 6, pp. 2080–2089, 1999. View at Scopus
  107. J. Ljusberg, Y. Wang, P. Lång et al., “Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts,” The Journal of Biological Chemistry, vol. 280, no. 31, pp. 28370–28381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Ljusberg, B. Ek-Rylander, and G. Andersson, “Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases,” Biochemical Journal, vol. 343, no. 1, pp. 63–69, 1999. View at Publisher · View at Google Scholar · View at Scopus
  109. B. Ek-Rylander, M. Flores, M. Wendel, D. Heinegard, and G. Andersson, “Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro,” The Journal of Biological Chemistry, vol. 269, no. 21, pp. 14853–14856, 1994. View at Scopus
  110. T. Sugimoto, “Anti-RANKL monoclonal antibody Denosumab (AMG162),” Clinical Calcium, vol. 21, no. 1, pp. 46–51, 2011. View at Scopus
  111. P. E. Lipsky, D. M. F. M. Van Der Heijde, S. Clair et al., “Infliximab and methotrexate in the treatment of rheumatoid arthritis,” The New England Journal of Medicine, vol. 343, no. 22, pp. 1594–1602, 2000. View at Publisher · View at Google Scholar · View at Scopus
  112. J. S. Smolen, C. Han, M. Bala et al., “Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1020–1030, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. G. Schett, K. Redlich, S. Hayer et al., “Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice,” Arthritis and Rheumatism, vol. 48, no. 7, pp. 2042–2051, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. E. Lubberts, L. van den Bersselaar, B. Oppers-Walgreen et al., “IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance1,” Journal of Immunology, vol. 170, no. 5, pp. 2655–2662, 2003. View at Scopus
  115. A. R. Pettit, H. Ji, D. Von Stechow et al., “TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis,” American Journal of Pathology, vol. 159, no. 5, pp. 1689–1699, 2001. View at Scopus
  116. E. Lubberts, L. A. B. Joosten, M. Chabaud et al., “IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion,” Journal of Clinical Investigation, vol. 105, no. 12, pp. 1697–1710, 2000. View at Scopus
  117. J. L. Kim, S. W. Kang, M. K. Kang et al., “Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts,” Journal of Cellular Biochemistry, vol. 113, no. 1, pp. 247–259, 2012.
  118. H. W. Jung, J. K. Jung, K. H. Son, et al., “Inhibitory effects of the root extract of Dipsacus asperoides C.Y. Cheng et al T.M. Ai on collagen-induced arthritis in mice,” Journal of Ethnopharmacology, vol. 139, no. 1, pp. 98–103, 2012.
  119. H. S. Kim, A. R. Kim, H. J. Park et al., “Morus bombycis Koidzumi extract suppresses collagen-induced arthritis by inhibiting the activation of nuclear factor-κB and activator protein-1 in mice,” Journal of Ethnopharmacology, vol. 136, no. 3, pp. 392–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Lewis and A. Levy, “Anti-inflammatory activities of Cassia alata leaf extract in complete Freund's adjuvant arthritis in rats,” West Indian Medical Journal, vol. 60, no. 6, pp. 615–621, 2011.
  121. K. Riehemann, B. Behnke, and K. Schulze-Osthoff, “Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-κB,” FEBS Letters, vol. 442, no. 1, pp. 89–94, 1999. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Sekiguchi, H. Mano, S. Nakatani, J. Shimizu, and M. Wada, “Effects of the Sri Lankan medicinal plant, Salacia reticulata, in rheumatoid arthritis,” Genes and Nutrition, vol. 5, no. 1, pp. 89–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. T. Shen, G. H. Li, X. N. Wang, and H. X. Lou, “The genus Commiphora: a review of its traditional uses, phytochemistry and pharmacology,” Journal of Ethnopharmacology, vol. 142, no. 2, pp. 319–330, 2012. View at Publisher · View at Google Scholar
  124. P. Suresh, C. N. Kavitha, S. M. Babu, V. P. Reddy, and A. K. Latha, “Effect of ethanol extract of trigonella foenum graecum (Fenugreek) seeds on Freund's adjuvant-induced arthritis in albino rats,” Inflammation, vol. 35, no. 4, pp. 1314–1321, 2012. View at Publisher · View at Google Scholar
  125. S. Ekambaram, S. S. Perumal, and V. Subramanian, “Evaluation of antiarthritic activity of Strychnos potatorum Linn seeds in Freund's adjuvant induced arthritic rat model,” BMC Complementary and Alternative Medicine, vol. 10, article 56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Mehta, N. K. Sethiya, C. Mehta, and G. B. Shah, “Anti-arthritis activity of roots of Hemidesmus indicus R.Br. (Anantmul) in rats,” Asian Pacific Journal of Tropical Medicine, vol. 5, no. 2, pp. 130–135, 2012.
  127. A. M. M. Fouda and M. Y. Berika, “Evaluation of the effect of hydroalcoholic extract of zingiber officinale rhizomes in rat collagen-induced arthritis,” Basic and Clinical Pharmacology and Toxicology, vol. 104, no. 3, pp. 262–271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Ratheesh, G. L. Shyni, and A. Helen, “Methanolic extract of Ruta graveolens L. inhibits inflammation and oxidative stress in adjuvant induced model of arthritis in rats,” Inflammopharmacology, vol. 17, no. 2, pp. 100–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. H. Yu, S. H. Venkatesha, S. Nanjundaiah, L. Tong, and K. D. Moudgil, “Celastrus treatment modulates antigen-induced gene expression in lymphoid cells of arthritic rats,” International Journal of Immunopathology and Pharmacology, vol. 25, no. 2, pp. 455–466, 2012.
  130. H. S. Kim, A. R. Kim, J. M. Lee, et al., “A mixture of Trachelospermi caulis and Moutan cortex radicis extracts suppresses collagen-induced arthritis in mice by inhibiting NF-kappaB and AP-1,” Journal of Pharmacy and Pharmacology, vol. 64, no. 3, pp. 420–429, 2012.
  131. H. He, X. Ren, X. Wang, et al., “Therapeutic effect of Yunnan Baiyao on rheumatoid arthritis was partially due to regulating arachidonic acid metabolism in osteoblasts,” Journal of Pharmaceutical and Biomedical Analysis, vol. 59, pp. 130–137, 2012.
  132. J. D. Lee, J. E. Huh, Y. H. Baek, K. C. Cho, D. Y. Choi, and D. S. Park, “The efficacy and mechanism action of RvCSd, a new herbal agent, on immune suppression and cartilage protection in a mouse model of rheumatoid arthritis,” Journal of Pharmacological Sciences, vol. 109, no. 2, pp. 211–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. X. Cai, H. Zhou, F. W. Yuen et al., “Suppressive effects of QFGJS, a preparation from an anti-arthritic herbal formula, on rat experimental adjuvant-induced arthritis,” Biochemical and Biophysical Research Communications, vol. 337, no. 2, pp. 586–594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  134. X. Shen, C. Li, H. Zhao et al., “Inhibitory effects of a traditional Chinese herbal formula TBL-II on type II collagen-induced arthritis in mice,” Journal of Ethnopharmacology, vol. 134, no. 2, pp. 399–405, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. F. F. Y. Lam, I. W. M. Ko, E. S. K. Ng, L. S. Tam, P. C. Leung, and E. K. M. Li, “Analgesic and anti-arthritic effects of Lingzhi and San Miao San supplementation in a rat model of arthritis induced by Freund's complete adjuvant,” Journal of Ethnopharmacology, vol. 120, no. 1, pp. 44–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Rajaiah, D. Y. W. Lee, Z. Ma et al., “Huo-Luo-Xiao-Ling Dan modulates antigen-directed immune response in adjuvant-induced inflammation,” Journal of Ethnopharmacology, vol. 123, no. 1, pp. 40–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  137. Y.-H. Yang, R. Rajaiah, D. Y.-W. Lee, et al., “Suppression of ongoing experimental arthritis by a Chinese herbal formula (Huo-Luo-Xiao-Ling Dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 642027, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. R. X. Zhang, A. Y. Fan, A. N. Zhou et al., “Extract of the Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats,” Journal of Ethnopharmacology, vol. 121, no. 3, pp. 366–371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. S. M. Nanjundaiah, D. Y. Lee, Z. Ma et al., “Modified huo-luo-xiao-ling dan suppresses adjuvant arthritis by inhibiting chemokines and matrix-degrading enzymes,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 589256, 2012. View at Publisher · View at Google Scholar
  140. H. Yu, S. H. Venkatesha, and K. D. Moudgil, “Microarray-based gene expression profiling reveals the mediators and pathways involved in the anti-arthritic activity of Celastrus-derived Celastrol,” International Immunopharmacology, vol. 13, no. 4, pp. 499–506, 2012.
  141. H. Li, Y. Y. Zhang, H. W. Tan, Y. F. Jia, and D. Li, “Therapeutic effect of tripterine on adjuvant arthritis in rats,” Journal of Ethnopharmacology, vol. 118, no. 3, pp. 479–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Kamon, R. Zhao, and K. Sakamoto, “Green tea polyphenol (-)-epigallocatechin gallate suppressed the differentiation of murine osteoblastic MC3T3-E1 cells,” Cell Biology International, vol. 34, no. 1, pp. 109–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Ahmed, “Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise,” Arthritis Research and Therapy, vol. 12, no. 2, article 208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. K. Takayama, K. Ishida, T. Matsushita et al., “SIRT1 regulation of apoptosis of human chondrocytes,” Arthritis and Rheumatism, vol. 60, no. 9, pp. 2731–2740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. B. Chandran and A. A. Goel, “Randomized pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis,” Phytotherapy Research, vol. 26, no. 11, pp. 1719–1725, 2012. View at Publisher · View at Google Scholar